Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

November 17, 2025 updated by: Golnaz Yadollahikhales, Cedars-Sinai Medical Center

A Longitudinal Study Investigating the Effects of Photobiomodulation (PBM) on Cognitive Function and Alzheimer's Disease (AD)-Related Biomarkers in Individuals With Mild Cognitive Impairment (MCI) or Dementia Due to AD

The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to provide topical heating to elevate tissue temperature for temporary relief of muscle and joint pain, muscle spasm and stiffness associated with arthritis. It also increases blood circulation and relaxes muscle tissue. This device is being used "off-label," meaning it will be used in a way that is different than its cleared use.

We want to learn whether this light treatment can improve executive function, and whether it changes certain inflammatory and neurodegeneration related signals in the blood. To do this, we will apply the photobiomodulation device to your forehead. We will also ask you questions and give you cognitive tests before and after light treatment. We will also collect blood samples before and after treatment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Signed and dated informed consent form (either by subject or LAR)
  • Willingness and ability to comply with all study procedures
  • Age 55 to 89 years, inclusive
  • Clinical diagnosis of Mild Cognitive Impairment or mild dementia (CDR Global = 0-1; MoCA 16-25) due to probable Alzheimer's disease diagnosis
  • Ability to attend in-person sessions at Cedars-Sinai and adhere to weekly visits
  • Stable dose of Alzheimer's disease medications (e.g., donepezil, rivastigmine, memantine, galantamine) for at least 4 weeks prior to enrollment, if applicable

Exclusion Criteria:

  • Presence of significant neurological conditions other than AD (e.g., epilepsy, Parkinson, etc.)
  • History of Seizures
  • If patient holds neuroimaging showing space-occupying lesions
  • If patient holds imaging with Fazekas greater than or equal to 3, more than 2 lacunar infarcts, and/or more than 5 microhemorrhages
  • Current pregnancy or lactation (although unlikely in this population)
  • Participation in another clinical trial or investigational drug within the past 30 days
  • Active use of illicit substances or non-prescribed psychoactive drugs within the past 30 days.
  • Severe dementia due to Alzheimer's disease or another etiology
  • Physical or mental impairment that prevents the participant from complying with the cognitive testing battery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active photobiomodulation
1064nm photobiomodulation to be applied for 8 minutes total each session
1064nm transcranial photobiomodulation
Sham Comparator: Sham
only 5 seconds of photobiomodulation, to account for small amount of participants who reported an initial warm sensation upon stimulation
1064nm transcranial photobiomodulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NIH Toolbox
Time Frame: Baseline measurements will be performed prior to intervention, post-treatment (week 5), and lastly at the 3-month follow-up visit

Three validated NIH Toolbox tasks:

  1. Dimensional Change Card Sort Task (measure of cognitive flexibility)
  2. Flanker Inhibitory Control and Attention Test (a measure of inhibitory control and selective attention),
  3. Visual Reasoning Test (non-verbal and visual reasoning)
Baseline measurements will be performed prior to intervention, post-treatment (week 5), and lastly at the 3-month follow-up visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glial Fibrillary Acidic Protein (GFAP)
Time Frame: Will be performed at baseline and at 3 month follow up
Plasma GFAP concentration (pg/ml) measure using the S-PLEX Assay
Will be performed at baseline and at 3 month follow up
Neurofilament Light Chain (NfL)
Time Frame: Baseline and 3-month follow up
Plasma Neurofilament Light Chain (NfL) concentration (pg/ml) measure using the S-PLEX Assay
Baseline and 3-month follow up
Total Tau
Time Frame: Baseline and 3-month follow up
Plasma total tau concentration (pg/ml) measure using the S-PLEX Assay
Baseline and 3-month follow up
Interferon-γ (IFN-γ)
Time Frame: Baseline and 3-month follow up
Plasma GFAP concentration (pg/ml) measure using the V-PLEX Assay
Baseline and 3-month follow up
Interleukin-1β (IL-1β)
Time Frame: Baseline and 3-month follow up
Plasma IL-1β concentration measured using the V-PLEX assay
Baseline and 3-month follow up
Tumor Necrosis Factor-α (TNF-α)
Time Frame: Baseline and 3-month follow up
Plasma TNF-α concentration (pg/ml) measured using the V-PLEX assay
Baseline and 3-month follow up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Golnaz Yadollahikhales, MD, Cedars Siinai Medical Center Department of Neurology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 25, 2025

Primary Completion (Estimated)

August 28, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

November 1, 2025

First Submitted That Met QC Criteria

November 1, 2025

First Posted (Estimated)

November 4, 2025

Study Record Updates

Last Update Posted (Actual)

November 19, 2025

Last Update Submitted That Met QC Criteria

November 17, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY00004349

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All IPD that underlie results in a publication

IPD Sharing Time Frame

Starting 6 months after publication all IPD and supporting information will be made available

IPD Sharing Access Criteria

All information regarding participants' data on primary and secondary outcome measures that will be used in publication

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.